Komboglyze granted EU marketing authorisation

 The European Commission has granted Komboglyze (saxagliptin and metformin HCl immediate-release fixed dose combination) a marketing authorisation for adults with type II diabetes.

The indication is an adjunct to diet and exercise to improve glycaemic control after the medication demonstrated favourable results in clinical trials.

Komboglyze combines the recently approved Onglyza (saxagliptin), a DPP-4 inhibitor, and metformin immediate-release (metformin IR), a biguanide, in a convenient tablet.

The approval covers the 27 Member States of the European Union.

By the end of this year, it’s expected that nearly 53 million people aged between 20 and79 in Europe will suffer from diabetes. This figure is expected to rise to more than 64 million by 2030.

The treatment is another compound developed by Bristol-Myers Squibb and AstraZeneca’s collaboration, started in 2007, aimed at researching and commercialising select investigational products for type II diabetes.